Skip to content

Study · Not a test of the peptide alone · 2009

2 results

Overexpression of thymosin beta4 increases pseudopodia formation in LNCaP prostate cancer cells.

Ito M, Iguchi K, Usui S, Hirano K

Biological & pharmaceutical bulletin1 Jun 2009Cited by 8 (Europe PMC)

PMID19483323 (opens in a new tab)DOI10.1248/bpb.32.1101 (opens in a new tab)PepBankPUB-19483323
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In human LNCaP prostate cancer cells, thymosin beta4 expression promoted formation of actin-based pseudopodia-like extensions.

    In plain wordsIn lab-grown prostate cancer cells, higher thymosin beta4 expression increased the formation of cell extensions linked to movement.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreasePseudopodia formation with thymosin beta4 expression
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In the present study, we found that thymosin beta4 expression promotes the formation of actin-based pseudopodia-like extensions, associated with cell migration, in human prostate cancer LNCaP cells.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Mechanism

    In thymosin beta4-overexpressing LNCaP cells, the PI3K inhibitor wortmannin and the Rho family inhibitor toxin B significantly reduced pseudopodia formation.

    In plain wordsIn lab-grown prostate cancer cells that make extra thymosin beta4, two pathway-blocking drugs reduced formation of cell extensions.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreasePseudopodia formation with wortmannin or toxin B in thymosin beta4-overexpressing cells
    Study

    humann: not reported in source

    LNCaP prostate cancer cells
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Treatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin and Cdc42/Rac1/RhoA inhibitor Clostridium difficile toxin B significantly reduced pseudopodia formation in thymosin beta4-overexpressing LNCaP cells, suggesting that the pseudopodia formation by thymosin beta4 is probably i…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.